The world's first resistant anti -tumor drug is successfully developed in Wuhan

On July 10, the reporter learned from the School of Chemistry of Huazhong Normal University that the precision intelligent medicine team led by doctoral students Wang Mingshu has made new progress in the field of organ specific drug design. Because it is difficult to target specific tissue organs with drug design, the drug design method design is often systemic. Systemic drugs will have side effects in other normal tissues except lesions. Therefore, new design strategies need to be designed to design small organs -specific drugs.

The school's precise intelligence team is based on the characteristic organization of the micro -ecological media distribution (TNMDD), and proposes a strategy based on distribution and metabolism. Specific distribution to improve drug safety. As a concept verification, the team designed a gastric acid inhibitory drug SH-337. The SH-337 showed a specific distribution in the stomach for a long time, and quickly removed from the body partition. Compared with the FDA-approved acidic drug Vorozan, SH-337 has better efficacy and higher safety. This study provides proof for the concept verification of DMBDD and provides a new perspective for developing efficient and low -toxic organ specific drugs. The paper is published in Research.

Tumor is the first killer of human health. A targeted drugs are a popular new therapy. Although the effect is good, drug resistance has become a century problem. How to solve drug resistance is the primary challenge of the industry. The traditional solution strategy is to develop new drugs after clinical resistance to drug resistance. This "dead sheep replenish" R & D model often makes many patients use no medicine to use and lose their lives. The precision intelligence team led by Dr. Wang Mingshu, grinding a sword for ten years, took the lead in putting forward a new idea of ​​resistance to resistant drug design based on resistance prediction, setting up the world's most complete kinase inhibitors fragmented library, and created the world's first high -precision The resistance prediction tool finally achieved a breakthrough in the design of resistance drug molecular.

This idea has been verified in the research and development of drugs targeting TRK. Data show that the drug -based drugs are completely invalid for resistance to resistance, and the newly designed targeted drugs are efficiently efficient for all clinical mutants and overcomes multiple drug resistance. At present, the team has reached preliminary cooperation intentions with a number of pharmaceutical leading companies to promote the clinical transformation of the project.

Wang Mingshu said that tumor patients should no longer be troubled by drugs, and provide Chinese solutions to solve tumor resistance.

(Source: Changjiang Cloud)

【Edit: Zheng Xiaoxiao】

For more exciting content, please download the "Da Wuhan" client in the major application markets.

- END -